NRXPW (NRXPW) Stock Price & Analysis
NRXPW (NRXPW) rose 0.00% to USD 0 as of June 10, 2026 at 12:05 UTC, according to Nexqual real-time market data.
NRXPW last closed at USD 0; the session ranged USD 0–0 on volume of 176,260 shares. Market capitalization is —, with a 52-week range of USD 0–0 (NCM). Source: Nexqual, June 10, 2026 at 12:05 UTC.
Key Statistics (as of June 10, 2026 at 12:05 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0.16 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 176,260 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (NRXPW)
Nexqual's technical model rates NRXPW "SELL" based on 2 bullish and 5 bearish signals across 58 daily candles, as of June 10, 2026 at 12:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.01) |
| MACD | -0 (negative) |
Analyst Ratings (NRXPW)
Wall Street analysts rate NRXPW "None", per Nexqual as of June 10, 2026 at 12:05 UTC.
| Consensus Rating | None |
|---|
Earnings (NRXPW)
| Revenue Estimate | $1.07M |
|---|
Source: Nexqual, June 10, 2026 at 12:05 UTC.
Financials & Fundamentals (NRXPW)
| Total Revenue | $2.29M |
|---|---|
| Gross Margin | +50.46% |
| Operating Margin | -444.57% |
| Profit Margin | +0.00% |
| Current Ratio | 0.29 |
| Total Cash | $6.71M |
| Total Debt | $934,000 |
| Free Cash Flow | $-8.54M |
Source: Nexqual, June 10, 2026 at 12:05 UTC.
Financial Health Score (NRXPW)
Nexqual rates NRXPW's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $7M cash, no debt |
| Cash Flow | Weak — FCF negative: -$9M, burning cash |
| Efficiency | Mixed — No data |
Ownership (NRXPW)
| Float | 30.45M |
|---|
Source: Nexqual, June 10, 2026 at 12:05 UTC.
Leadership (NRXPW)
NRXPW is led by Jonathan C. Javitt M.D., M.P.H. (age 68), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 12:05 UTC.
| Co-Founder, Chairman & CEO | Jonathan C. Javitt M.D., M.P.H. (age 68) |
|---|---|
| CFO & Treasurer | Michael S. Abrams (age 55) |
| Chief Operating Officer | Joseph M. Casper (age 74) |
| Chief Strategy Officer & Director | Dennis K. McBride (age 70) |
Major Backers & Investors (NRXPW)
Notable institutional backers of NRXPW include Wolverine Asset Management, LLC, according to Nexqual as of June 10, 2026 at 12:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wolverine Asset Management, LLC | 6.58% |
Source: Nexqual, June 10, 2026 at 12:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NRXP | NRX Pharmaceuticals, Inc. | USD 3.87 | ▼ 6.52% |
| QSIAW | Quantum-Si incorporated | USD 0.01 | ▼ 95.94% |
| NLSPW | NLS Pharmaceutics Ltd. | USD 0.02 | ▲ 0% |
| JSPRW | Jasper Therapeutics, Inc. | USD 0.01 | ▼ 33.33% |
| SABSW | SAB Biotherapeutics, Inc. | USD 0.01 | ▼ 66.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:05 UTC. This page is informational and not investment advice.